Legal Representation
Attorney
Monica Riva Talley
USPTO Deadlines
Next Deadline
285 days remaining
Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20201013)
Due Date
October 13, 2026
Grace Period Ends
April 13, 2027
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
33 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 13, 2025 | REM3 | E | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | Loading... |
| Jan 31, 2025 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| May 30, 2024 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| May 30, 2024 | ECDR | I | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | Loading... |
| May 30, 2024 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| May 30, 2024 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| May 30, 2024 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| May 30, 2024 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Nov 19, 2021 | ADCH | M | CHANGE OF NAME/ADDRESS REC'D FROM IB | Loading... |
| Feb 20, 2021 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
| Jan 29, 2021 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
| Jan 29, 2021 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
| Jan 13, 2021 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| Oct 13, 2020 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jul 31, 2020 | GPNX | P | NOTIFICATION PROCESSED BY IB | Loading... |
| Jul 28, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jul 28, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jul 15, 2020 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Jul 15, 2020 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | Loading... |
| Jul 8, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jun 20, 2020 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| May 28, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| May 28, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| May 28, 2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Dec 20, 2019 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Nov 30, 2019 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Nov 30, 2019 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Nov 10, 2019 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Nov 9, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Nov 4, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 8, 2019 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Oct 2, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Sep 26, 2019 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
Chemical reagents for medical and veterinary purposes; Medical and pharmaceutical preparations comprising liposomes, lipoplexes, polyplexes, microparticles, nanoparticles, or lipid-based emulsions for the treatment and prevention of cancerous diseases, infectious diseases, autoimmune disorders, genetic defects or metabolic disorders; Medical and pharmaceutical preparations comprising, in particular, liposomes, lipoplexes, polyplexes, microparticles, nanoparticles, or lipid-based emulsions and comprising additional active ingredients, in particular proteins or nucleid acids for the treatment and prevention of cancerous diseases, infectious diseases, autoimmune disorders, genetic defects or metabolic disorders; Carriers and carrier systems, namely, drug delivery agents in the form of powders, tablets, liposomes, lipoplexes, polyplexes, microparticles, nanoparticles, or lipid-based emulsions and capsules that provide controlled release of the active ingredients for pharmaceuticals for use in the treatment of cancer, infectious diseases, autoimmune disorders, genetic defects, and metabolic disorders
Class 042
Scientific research for medical and veterinary purposes, in particular for treatment of cancer, infectious diseases, autoimmune disorders, genetic defects, and metabolic disorders, using liposomes, lipoplexes, polyplexes, microparticles, nanoparticles, or emulsions
Class 044
Medical and veterinary services in connection with cancer diseases, infectious diseases, autoimmune disorders, genetic defects, and metabolic disorders
Classification
International Classes
005
042
044